Literature DB >> 23053669

Is it time to abandon RHAMM/HMMR as a candidate antigen for immunotherapy of acute myeloid leukemia?

Dolores J Schendel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23053669      PMCID： PMC3487544          DOI： 10.3324/haematol.2012.077099

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.

Authors:  Sylvia Snauwaert; Stijn Vanhee; Glenn Goetgeluk; Greet Verstichel; Yasmine Van Caeneghem; Imke Velghe; Jan Philippé; Zwi N Berneman; Jean Plum; Tom Taghon; Georges Leclercq; Kris Thielemans; Tessa Kerre; Bart Vandekerckhove
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

2.  MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.

Authors:  Matthias Leisegang; Susanne Wilde; Stefani Spranger; Slavoljub Milosevic; Bernhard Frankenberger; Wolfgang Uckert; Dolores J Schendel
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

3.  TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.

Authors:  Stefani Spranger; Irmela Jeremias; Susanne Wilde; Matthias Leisegang; Lilian Stärck; Barbara Mosetter; Wolfgang Uckert; Mirjam H M Heemskerk; Dolores J Schendel; Bernhard Frankenberger
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

4.  Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.

Authors:  Jochen Greiner; Li Li; Mark Ringhoffer; Thomas F E Barth; Krzysztof Giannopoulos; Phillipe Guillaume; Gerd Ritter; Markus Wiesneth; Hartmut Döhner; Michael Schmitt
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

5.  High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.

Authors:  Jochen Greiner; Anita Schmitt; Krzysztof Giannopoulos; Markus T Rojewski; Marlies Götz; Isabel Funk; Mark Ringhoffer; Donald Bunjes; Susanne Hofmann; Gerd Ritter; Hartmut Döhner; Michael Schmitt
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

6.  Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.

Authors:  Jochen Greiner; Mark Ringhoffer; Masanori Taniguchi; Anita Schmitt; Dieter Kirchner; Gertraud Krähn; Volker Heilmann; Jürgen Gschwend; Lothar Bergmann; Hartmut Döhner; Michael Schmitt
Journal:  Exp Hematol       Date:  2002-09       Impact factor: 3.084

7.  RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.

Authors:  Michael Schmitt; Anita Schmitt; Markus T Rojewski; Jinfei Chen; Krzysztof Giannopoulos; Fei Fei; Yingzhe Yu; Marlies Götz; Marta Heyduk; Gerd Ritter; Daniel E Speiser; Sacha Gnjatic; Philippe Guillaume; Mark Ringhoffer; Richard F Schlenk; Peter Liebisch; Donald Bunjes; Hiroshi Shiku; Hartmut Dohner; Jochen Greiner
Journal:  Blood       Date:  2007-10-31       Impact factor: 22.113

Review 8.  Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells.

Authors:  Jochen Greiner; Lars Bullinger; Barbara-ann Guinn; Hartmut Döhner; Michael Schmitt
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

9.  mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies.

Authors:  Jochen Greiner; Mark Ringhoffer; Masanori Taniguchi; Li Li; Anita Schmitt; Hiroshi Shiku; Hartmut Döhner; Michael Schmitt
Journal:  Int J Cancer       Date:  2004-02-20       Impact factor: 7.396

Review 10.  Graft-versus-leukemia effects of transplantation and donor lymphocytes.

Authors:  Hans-Jochem Kolb
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.